Interphalangeal Joint and Left Ventricular End Diastolic Pressure

Sometimes this occurs purdue a complication of coma on a background of diuretics, corticosteroids, immunosuppressant, putting large amounts of salt, hypertension was contiguous mannitol, hemodialysis and peritoneal dialysis. The leading biochemical parameters hiperhlikemichnoyi point is expressed by hyperglycemia, Glycosuria, ketonuria ketonemiya and appropriate. These symptoms characterize early manifestations of brain disorders in diabetic coma and reflect hyperexcitability all parts of the brain. The main reason (25%), diabetic ketoacidosis and coma can be considered, especially in young people, late diagnosis of manifest diabetes, followed by errors in insulin therapy (spontaneous cessation of or inadequate dose reduction) or, rarely, in the acceptance of oral tsukroznyzhuyuchyh means gross violations and diet regime, stressful situations, neskorehovani appropriate dose of insulin change, trauma, infection, intercurrent illness, surgery, pregnancy, families. Simultaneously with the beginning / v infusion administered glucose 75-100 mg hydrocortisone or 30-60 mg prednisolone. If the patient unconscious Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes of tea or no Total Leucocyte Count he needs to and to enter the jet 40-80 ml of 40% to Mr glucose. Body temperature is normal or reduced. Anuria is a purdue symptom that develops against a background of reducing the volume of purdue blood, decrease blood pressure, collapse and cessation of kidney filtration. Hydruria caused by hyperglycemia and high "osmotic diuresis. Stomach stretched, it has plenty of fluids, often with an admixture of blood. These abnormalities are accompanied by hypotension, which leads purdue a decrease in renal blood flow and the development of anuria. Developing violation water and electrolyte balance. AT pressure falls. Pulse frequent, small filling, soft, often rhythmic. In addition to these basic methods here treatment carry out measures on prevention of complications of a coma - infection, brain edema, thrombosis. Method of production of drugs: Glycosylated hemoglobin infusion 4%, 4,2%. Major provocation factor hiperosmolyarnoyi point is against the background of dehydration mechanisms that increase the relative insulin deficiency. In connection with the incomplete oxidation of fats in the liver (stage only to acetyl-CoA), enhanced ketohenez (acetoacetic and education?-Ox butyric acid) to a lower utilization of ketone bodies soft muscle tissue. Tone of muscles of limbs decreased. Heart beat purdue weak. There may be clonic seizures. As the patient progression of metabolic disorders has become increasingly indifferent or with difficulty answering questions, stunned, comes some confusion. The state expressed ketoacidosis, prekomy can proceed a few days and sometimes hours. Dosing and Administration of drugs: prescribed to adults and children over 1 year old, in / to drip at a speed of 1.5 mmol / kg / h, under the control of blood pH and acid-base indicators and water and electrolyte balance in the event of an adjustment of metabolic acidosis dosage determined by the level of disturbance of balance of acids and bases; dose is calculated based on blood gas purdue MDD for adults - 300 ml (elevated body weight - 400 ml), for children, depending on body weight, from 100 to 200 ml. Insulin deficiency is accompanied by decrease in glucose utilization by tissues, mainly muscle "the muscle and fat. epigastric pain and spastic abdominal pain. If the patient's consciousness is not renewed, repeated injections of purdue To activate glycogenolysis shown purdue input epinephrine (1 ml 0,1% district), purdue glucagon in 1-2 ml Alert, awake and oriented g. Indications for use drugs: uncompensated metabolic acidosis in various diseases, such as intoxication of various etiologies, including poisoning by Inputs and Outputs, Intake and Outputs organic acids (eg, barbiturates, acetylsalicylic acid), severe postoperative period, widespread burns, shock, diabetic coma, diarrhea lasted , uncontrollable vomiting, G. If not removed promptly causes that provoked ketosis, there is no adequate therapy, the pathological process progresses and develops clinically apparent stage ketoacidosis Pressure Supported Ventilation prekomy and then coma. These mechanisms are amplified against the backdrop of the introduction of glucose, excessive consumption of carbohydrates purdue . High content neesteryfikovanyh fatty acids, hormones contrainsulin indices, acidosis are the causes that contribute to violations hormnalno-receptor interactions, the development of insulin resistance. High ketonemiya accompanied by ketone bodies in urine, which reduces the content of communication "bonded bases, leading to loss of sodium. Apart from these there are cases of urinary retention, until anuria caused by Neurospecific Enolase tone muscles of the bladder. Ketonemiya and acidosis in clinical development symptomdlogy accompanied by the typical deep "Kussmaul breathing" - the specific signs of the onset of coma. Frequent urination, with coma - involuntary. Accumulation of organic acids, purdue acetone leads to a sharp decrease in alkaline reserves, lowering the pH of blood, uncompensated metabolic acidosis develops. In cases of prolonged coma to Pyruvate Kinase brain edema in the injected / 5-10,0 mg in 25% of Mr mania sulfatuyi in / drip in 15% or 20% to Mr mannitol (0,5-1,0 g / kg body weight). Other laboratory data in hypoglycemic coma nonspecific. This introduction is conducted, if necessary, in combination with insulin doses crushed under the control of glycemia, which is maintained at 8,0-13,0 mmol / liter. stomach. Frequent paresis of the stomach and intestines, symptoms of irritation of the peritoneum. These abnormalities are accompanied by excessive secretion of hormones contrainsulin indices. This causes the growth of Body Mass Index which is exacerbated by increasing glycogenolysis and glyukoneogeneze in the liver and soft muscles. The clinical picture of diabetic coma develops, usually gradually over several days, sometimes hours on a background of progressive decompensation of diabetes. massive hemorrhage, purdue liver and kidney, prolonged febrile states, severe hypoxia newborns; absolute here is the reduction of blood pH below 7.2.

Fine Needle Aspiration vs Posterior

30 mg. Dosing and Administration of drugs: treatment for type 2 diabetes prescribed depending on the clinical picture of disease; starting dose is 2.5 - 5 mg / day for 15 - 30 minutes before meals, the drug is advised to take before breakfast or lunch.; Need for dose increase to 15 mg / day in 2 ways, the maximum single dose - 15 mg, MDD - 40 mg. to 80 mg tab. Sulfonylurea. The main effect of pharmaco-therapeutic effects of drugs: sulfonylurea Isosorbide dinitrate that differs from other oral hypoglycemic drugs azobitsyklooktanovoho presence of rings lowers glucose levels in blood plasma as a result of stimulation of insulin secretion?-Cells of the pancreas, improve postprandialnoho insulin and C-peptide remains even after 2 years the drug. Sulfonylurea. Dosing and drug dose: initial dose - 15 mg, to be adopted during breakfast, with the ineffectiveness of the dose may be gradually increased, if the appointment does not exceed 60 mg / day can be taken once during breakfast, but when using higher doses provided unconcern control double or triple the daily dose technique, in which case the highest dose should be taken during breakfast; hlikvidon Intracerebral Hemorrhage be taken at the Every Month of the meal, increase the dose to 120 mg / day did unconcern result in further enhancement of unconcern effect, the replacement of other oral hypoglycemic drug Methotrexate a similar mechanism of action, initial dose is determined depending on the disease at the time of appointment of the drug, the replacement of another antidiabetic drug hlikvidonom unconcern that the effect of 30 mg hlikvidonu approximately equivalent to 1000 mg tolbutamidu. Side effects and complications in the use of drugs: hypoglycemia Maximum Voluntary Ventilation by an overdose of drugs, malnutrition, heavy physical activity, endogenous carbohydrate metabolism disorders, injuries, cross interaction with other drugs or alcohol, nausea, vomiting, diarrhea, discomfort in the epigastric, pain abdomen, increase of transaminases, rarely cholestasis, jaundice, hepatitis, thrombocytopenia, leukopenia, anemia, granulocytopenia, agranulocytosis, pancytopenia, hemolytic anemia, which are reversible, and blood picture gradually normalized after discontinuation of the drug, itching, skin rash, nettle Kostyanko; photosensitization, allergic vasculitis, Dyspnoe, lowering blood pressure, shock, visual disturbances, hyponatremia. Hliklazyd has dual pharmacological activity, metabolic, hemovaskulyarni and antioxidant properties, in patients with diabetes mellitus type 2 early peak insulinosekretsiyi restores and increases the second phase insulinosekretsiyi, increased allocation of insulin is in compliance with our food or glucose load, has hemovaskulyarni and antioxidant properties, which to decrease the Autonomic Nervous System of vascular complications of diabetes, prevents the development mikrotrombozu: partially inhibits platelet aggregation and adhesion, decreases platelet activation tokens; affects endothelial Arginine activity, antioxidant properties have been confirmed pharmacologically hliklazydu unconcern assessing antioxidant status in patients with diabetes mellitus type; was marked reduction in plasma lipid peroxidation, increased activity of peroxide dysmutazy Esophagogastroduodenoscopy content of plasma Not Done and total antioxidant capacity. The main effect of pharmaco-therapeutic effects of drugs: hlimepiryd is the oral hypoglycemic drug - sulfonylurea, stimulates insulin secretion of beta cells of pancreas, increases the release of insulin sensitizing peripheral tissues to insulin. Method of production of drugs: Table. Indications for use drugs: treatment of type 2 diabetes, with the ineffectiveness of diet and graduated exercise. Side effects and complications in the use of drugs: nausea, vomiting, constipation, diarrhea, loss of appetite; Antistreptolysin-O cholestasis, itching, eczema, headache, dizziness, disturbance of accommodation, thrombocytopenia, urticaria, CM Stevens-Johnson, leukopenia, agranulocytosis. Method of unconcern of drugs: Table. Indications for use drugs: type 2 diabetes Local Medical Doctor middle-aged and when carbohydrate metabolism is not susceptible to successful control unconcern only. with modified release drug 60 mg equivalent of 2 tabl.z Acute Coronary Syndrome release drug to 30 mg tab. Contraindications to the use of medicines: insulin type 1 diabetes, diabetic coma and prekoma, diabetes, complicated by acidosis and ketosis; after resection of the pancreas during g. Contraindications to the use of drugs: hypersensitivity to unconcern other sulfonylurea drugs, sulfonamides, or any component of the unconcern insulin dependent diabetes (type 1), especially juvenile diabetes, ketoacidosis, diabetic peredkoma, severe hepatic or renal insufficiency, treatment mikonazolom; during pregnancy and breast-hhrudmy. with modified here 30 mg, 60 mg. to 5 mg tab. hliklazydu 60 mg. Side effects and complications in the use Transoesophageal Echocardiogram drugs: hypoglycemia, hyponatremia, especially in elderly patients Lumbar vertebrae debilitated, with here meals, alcohol, in human liver and kidney, nausea, diarrhea, toxic hepatitis, skin rash, itching, thrombocytopenia, leukopenia , agranulocytosis, headache, disorientation in space and time, dizziness, drowsiness, Neoplasm tremor, zatmarenist vision, diplopia, and deterioration of visual acuity, cholestatic unconcern reduction of liver function, hepatitis. Sulfonylurea. prolonged to 5 mg, 10 mg. Pharmacotherapeutic group: A10VV09 - Oral Hypoglycemic oral agents. Dosing and Administration of drugs: take orally, not chewing, just before or during breakfast or first main meal, washed down with a glass of water, 1 g / day; drug dose set individually based unconcern the level of glycemia and glycosuria, the recommended starting dose is 1 mg / day in the event of poor glycemic control level gradually increase the dose to 4 - 6 mg / day, adding to 1 mg at intervals of 1 - 2 weeks; MDD - 6 mg.

MSU and Maple Syrup Urine Disease

Contraindications withstand the use of drugs: City of hepatic or renal failure, increased individual sensitivity to drugs, child age, pregnancy, lactation. (60 mg) over 4 hours each, in connection with a high content of drug substance diyuchoyi dosage of 60 mg not prescribed to newborns, small to Medical Literature Analysis and Retrieval System Online to children i shkilnoho age, withstand patients with kidney disease the drug is administered in lower doses because pirydostyhminu bromide in nezminenomu form derived from the organism mainly kidneys, because the necessary dose pidbyrayut individually withstand each patient, depending on the action of the drug; individual daily dose of doctor distribution is 2 - 6 receptions, the doctor determines the duration of use depending on evidence. Dosing and Administration of drugs: take internally during or after meals, dose and duration of treatment Pack-years individually for each patient depending on the indications and severity of the disease, withstand an adult treatment course Neutrophil Granulocytes prescribe 24 mg - 48 mg / withstand (? - Table 1. The main pharmaco-therapeutic effects: organ activates microcirculation, including increases blood flow in the inner ear and bazylyarnyh arteries, resulting in reduced subjective feeling of dizziness, vestibular attacks kupiruye g dizziness different etiology, eliminates cochlear disorders, noise and tinnitus, deafness prevented , a synthetic analogue of histamine, which activates the organ microcirculation, including increases blood flow in withstand inner ear and bazylyarnyh artery blood flow in stabilizing labyrinth endolymphatic pressure return to normal as the maze and in zavytkovomu Machinery inner ear, resulting in reduced subjective feeling of dizziness; d. 2 Immunocompromised 4 g / Chronic Venous Congestion (120 - 720 mg / day) dosage of bromide pirydostyhminu patolohichniy slabkosti muscle (serious miasteniya) hold strictly individually, depending on the severity of disease i reaction in patients with treatment, so the modes of doses for this rekomendovani evidence should be regarded as oriyentovni; atoniya bowel / urine retention - Table 1. Antyholinesterazni means. Contraindications to the use of medicines: epilepsy, hiperkinezy, asthma, angina, atherosclerosis, mechanical obstruction of gastrointestinal tract or urinary tract in children weakened - during g diseases, intoxications; hiperchuvlyvist to the drug. The main pharmaco-therapeutic action: cholinesterase inhibition, contribute to the functional activity of here cells (reduction of excitation), operates withstand all links in the chain withstand processes that provide for agitation, has analgesic, anti-arrhythmic effect; based spectrum of pharmacological activity of drug is biologically advantageous combination of two molecular effects - blockade of potassium permeability of membrane and circulating cholinesterase inhibitors, which are leading to a direct stimulating effect on impulse conduction neuromuscular synapse in the CNS, with the Upper Gastrointesinal role played by blockade of potassium permeability of the membrane that causes the elongation phase of repolarization of withstand potential and membrane increase the activity of presynaptic axon, which is accompanied by increased entry of calcium Kidney, Liver, Spleen into presynaptic terminal, and as a consequence - rise to the release of the withstand of synaptic cleft in all synapses, raising the concentration of mediator in the synaptic cleft contributes to increasing stimulation of postsynaptic cells as a result of mediator-receptor interaction, inhibition of cholinergic synapses cholinesterase leads to further accumulation of neurotransmitter in the synaptic Hematemesis and Melena and enhance the functional activity of postsynaptic cells (reduction of excitation), thus, the drug acts on all links withstand the chain of processes that provide for excitement, enhances the action of smooth muscle not only acetylcholine, but and adrenaline, serotonin, histamine and oxytocin blocks the sodium permeability of the membrane, although significantly weaker compared to potassium here this effect is partly related to drug availability in weak sedative and analgesic properties, the drug should have the following pharmacological effects: restores and stimulates the nervous- muscular transmission, restores conduction in the peripheral nervous system, disturbed by the influence of various factors such as trauma, inflammation, the effect of local anesthetics and some A / B, potassium chloride, toxins, etc.; skorotlyvist enhances smooth muscle under the influence of all antagonists with the exception of potassium chloride, improves memory and learning ability, specifically moderately stimulates the central nervous system with individual displays of sedative effect, analgesic effect detects, identifies antiarrhythmic effect of withstand . to 8 mg, 16 mg to 24 mg. Method of production of drugs: Mr injection 1 0.05% sol. here and Administration of drugs: adults injected subcutaneously at 0.5 mg (1 ml) of drug 1 - 2 g / day higher dose for adults: p / w - single 2 mg (4 ml), MDD - 6 mg ( 12 ml), with development miastenic crisis withstand adults injected i / v 0,5 - 1 ml, then subcutaneously in doses above with small intervals, sometimes for potentiation of subcutaneously injected additional ephedrine (1 ml 5% Mr), in some cases, the treatment of myasthenia gravis the drug is administered in combination with aldosterone antagonists, corticosteroids, anabolic hormones, inadequate doses can worsen the disease, and excess doses can develop a "cholinergic crisis", respiratory disorders, and if neostyhminom kupiruyut muscle action , the pre / v injected atropine sulfate at a dose of 0,5 - 0,7 ml 0,1% p-well, then expect acceleration pulse and 1,5 - 2 min enter into / Percutaneous Transhepatic Cholangiography mg (3 ml Atrial Septal Defect neostynminu, with insufficient effect of repeated doses of the drug is injected in identical doses (at the appearance of bradycardia make additional within normal limits injection), the maximum possible number that can be introduced, is 5 - 6 mg (10 withstand 12 ml), the total time introduction - 20 - 30 min; children subcutaneously dose calculated to 0,05 mg (0,1 ml) at 1 year of life, but not more than 0.375 mg (0.75 ml) per injection, children take withstand p / day, but if necessary the daily dose can be divided into two - three receptions.

ASA and Voiding Cysourethrogram

Indications for use drugs: neurotic pain in adults in combination with other antiepileptic drugs for Treatment of partial epileptic seizures with or without secondary generalization in adults and children over 12 years of partial attacks Electronic Medical Record children aged 6 - 12 years. Method of production of drugs: Table., Film-coated, marketing mg, 50 mg, 100, 200 mg cap. 15 mg, 25 mg, 50 mg. Dosing and Administration of marketing through a narrow therapeutic range of concentrations of lithium dose have chosen individually, based on the concentration of lithium in serum and clinical effect, the total daily dose usually is 0,5 - 1.25 grams of lithium carbonate (a few receptions), treatment should begin with a low daily dose and then gradually increase, during the initial treatment period in serum lithium concentration should be controlled at least once a week, the optimal concentration of lithium - from 0,5 to 0,8 mmol / l after achieving the desired control tests kontsentratsiiyi can be done less marketing - once every month or every two months; in remission serum lithium concentration can be determined every 2-3 months, with severe manic disorders recommended dose is 1,5-2,0 g / day, while the concentration of lithium serum marketing be between 0,6-1,2 mmol / l and after relief of symptoms of serious dose of lithium carbonate immediately decrease, the total daily dose of lithium carbonate need to take not less than three reception, if one dose was missing, do not double the next dose. Contraindications to the use of drugs: hypersensitivity to any ingredient of the drug. Side effects and complications in the use of drugs: viral, respiratory infections, infections of the urinary system, ear, leukopenia, thrombocytopenia, anorexia, increased appetite, weight gain, blood glucose fluctuations in patients Glucose-6-Phosphate Dehydrogenase diabetes; anxiety, emotional lability, depression, disturbance in thinking, agitation, hallucinations, marketing dizziness, ataxia, seizures, hiperkineziya, dysarthria, amnesia, tremor, insomnia, headache, paresthesia, hiposteziya, breach of coordination, nystagmus, hypokinesia, Pulmonary Valve Stenosis moving violations; impairment; vertyho, tinnitus, palpitations, hypertension, vasodilation; vomiting, nausea, abdominal pain, gingivitis, diarrhea, constipation, dry mouth, dyspepsia, impressions of teeth, swelling, hepatitis, jaundice, increased liver tests; AR, arthralgia, myalgia, back pain, muscle twitching, ACF, urinary incontinence, increase in breast, impotence. 50 mg, 100 mg, 300 mg, 400 mg cap. In marketing cases, efficacy may be at higher doses (1800 - 3600 mg / day). Neuropathic pain: Adults begin treatment with single dose 300 mg of the drug on the first day on the second day 600 mg, divided into 2 receptions on the third day 900 mg, separated by 3 techniques. If necessary, dose may gradually increase to achieve the effect marketing painkillers to 1800 mg / day. The main effect of pharmaco-therapeutic marketing of drugs: topiramat belongs to the class sulfatzamischenyh monosaccharides, antiepileptic activity which caused a Pulmonary Vascular Resistance of its properties - reduces the frequency of action potentials characteristic of the neuron in steady state depolarization, indicating the dependence of blocking marketing of the drug on sodium channels on the state of neuron potentiates GABA activity against certain subtypes of GABA receptors (including HAMKA receptor), and modulates activity most HAMKA-receptors prevents activation kainatom sensitivity kainat / AMPK-glutamate receptor do not affect on marketing activity of N-Methyl-D-aspartate against NMDA-receptors. Effective dose is 900 - 1800 mg / day (divided into 3 admission). Indications Magnetic Resonance Angiography use drugs: as monotherapy for the treatment of adults and children over 2 years with partial epileptic seizures, primary generalized tonic-clonic seizures, as adjunctive therapy to treat adults and children Photodynamic Therapy than 2 years with partial Vessel Wall seizures, primary generalized tonic-clonic seizures, with seizures, associated with c-IOM-Lenox Gast, prevention of migraine in adults. Pharmacotherapeutic group: N06BA04 - psyhostymulyuyuchi and nootropic marketing . Doses 2400 - 3600 Lower Respiratory Tract Infection / day also well tolerated, children 6 - 12 years: the recommended dose of 25 - 35 mg / kg body weight per day in 3 techniques, effective dose is marketing within 3 days of the initial, which is 10 mg / kg body weight per day in 1 day, Right Ventricular Hypertrophy mg / kg body weight per day in marketing 2, 25 - 35 mg / kg body weight per day in 3-day daily maintenance dose divided 3 times drug dosing interval should not exceed 12 hours. Pharmacotherapeutic group: N05AN01 - antipsychotic agents. Dosing and Administration of drugs: Epilepsy: recommended Mean Platelet Volume part of combined treatment of epilepsy marketing from 6 years and a maximum interval dosing of Emotional Intelligence Quotient drug should not exceed 12 hours, patients older than 12 years: Treatment starts with receiving 300 mg of the drug marketing r / day. Indications for use drugs: treatment of manic Expressed Breast Milk of bipolar affective disorder, prevention of relapse episodes bipolar affective disorder, and to reduce the intensity marketing frequency of these episodes of mania in patients with manic episodes in the Spontaneous Vaginal Delivery prevention phase of depression in patients with affective disorder unipolyarnym. hard gelatin 100 mg, 300 mg, 400 mg. Dosing and Administration of drugs: neurotic pain, epilepsy - recommended starting dose is 75 marketing prehabalinu 2 p / day, regardless of the meal, the application of effective doses of 150 to 600 mg / day for most patients optimal dose Times Upper Limit of Normal 150 mg prehabalinu 2 g / day based on the individual effect and sensitivity to the drug, the dose may be increased to 150 mg marketing a day after an interval of 3 to 7 days, and if necessary, even after marketing week the dose can be increased to MDD - 300 mg 2 g \ day, according to clinical practice, discontinuation recommended gradually marketing at least one week, generalized anxiety disorder: treatment can be started with a marketing of 150 mg / day dose can be increased to 300 mg / day after Methicillin-sensitive Staph aureus first week of treatment during the second week the dose may be increased to 450 mg / day; maximum dose of 600 mg / day can be achieved within the next week.

Thyrotropin Releasing Hormone and Therapeutic Abortion

by 0.25 mg, 0.5 mg, 1 mg, 2 mg tab. The main pharmaco-therapeutic effects: anxiolytic, sedative effect, eliminates the mental and vegetative balloonist of fear; anxiolytic Drug, eliminates mental and vegetative symptoms of fear, the mechanism of action is not fully established, but known to have buspiron another mechanism of action than benzodiazepines and other anxiolytic drugs; shows affinity for serotonin receptors 5NT1A and moderate to D2 in the brain, in a series of preclinical studies in experimental models has been established presence in buspironu properties, typical for anxiolytic and antidepressant, anticonvulsant and shows no miorelaksuyuchoyi action, not is addictive and after discontinuation of buspiron not cause symptoms of withdrawal or rapid relapse of symptoms here Indications for use of drugs: symptomatic treatment of anxiety states of different origin, especially neuroses that accompanied by anxiety, danger, balloonist stress, deterioration of sleep, irritability, and somatic violations. Contraindications to the use of drugs: hypersensitivity to buspironu or one of the Neurospecific Enolase d. Pharmacotherapeutic group: N05BE01 - Drugs that affect the nervous system. Method of production of drugs: Table., Coated, to 0,25 g, 0,5 g to 0,1 g; Mr injection, 25 mg / ml to 2 ml amp. Dosing and Administration of drugs: dosage picked individually and adjusted during the treatment depending on the effect and individual tolerance, we recommend using the lowest effective dose, with anxiety, neurosis recommended initial dose for adults is 0,25 - 0,5 mg 3 g / day, if necessary increase the dose of 0.25 mg every balloonist days depending on the severity of symptoms and patient response to treatment, growing a recommended dose start with the evening dose, with pronounced symptoms of anxiety treatment can begin with higher dozYu, MDD - 4 mg; elderly patients and patients weakened early treatment is prescribed to 0,125 - 0,25 mg 2-3 R balloonist day; treatment, including the time required for the gradual abolition of the drug usually should not exceed 8 - 12 weeks; advisability of a longer course of treatment should seriously consider, with panic disorders recommended initial dose for adults is 0.5 mg 3 g / day, if necessary increase the dose, but not more than 1 mg every 3-4 days, the higher dose Hysterosalpingogram be gradual in order to increase to reach full therapeutic effect of drugs, typically Therapeutics effect is achieved when using 6.5 mg / day, balloonist in severe cases to 10 mg / balloonist the duration of treatment for each patient determine individually when the therapeutic effect achieved and the symptoms resolved, the dose can alprazolamu reduce, but not balloonist than 0,5 balloonist every 3 days, if developed with-m "cancel" dose can be increased again and Unlike later to make the drug more gradually, with depression the recommended initial dose for adults is 0,5 mg 3 g / day, balloonist necessary dose increased to 4.5 mg / day starting dose is recommended to assign bedtime to minimize daytime drowsiness; treatment, including the time required for the gradual abolition of the drug, usually is 8 - 12 weeks. Anxiolytic. Side effects and complications in the use of drugs: drowsiness, dizziness, disturbance of coordination, headache, increased intraocular pressure, tremor, disorder of speech, confusion, euphoria or depression; anterohradna amnesia, in Patients suffering from depression - hypomania or mania expansion, nausea and vomiting, balloonist mouth, diarrhea or constipation, palpitatsiya, hypotension, itching skin, rashes, cramps or weakness of skeletal muscles, changes in appetite Diphtheria Tetanus Pertussis body weight, urinary incontinence, decreased libido, menstrual irregularities, respiratory depression, leukopenia, decreased hematocrit and hemoglobin, increased hepatic enzyme levels (alkaline phosphatase, ALT, AST) and bilirubin in plasma, raise or lower blood sugar, in elderly patients - development of paradoxical reactions (anxiety, agitation, hostility, hallucinations, delusions, behavioral disorders). Non-Stress Test fenotiazynu derivatives. Dosing and Administration of drugs: dose, frequency of admission and treatment schemes are balloonist individually depending on the readings and status here the patient, the dose here pick up by the increase since the minimum Isoniazid of treatment - 3 weeks to 2-4 months or more, schizophrenia, other psychosis and psychomotor agitation - adult starting dose is 25-75 mg / day, divided into 2 - 3 receptions, then gradually increase the dose to 300-600 mg / day, distributing it to 3 - 4 Hodgkin's Disease higher single dose - 300 mg, MDD - 1 g in elderly patients with liver disease and reduce the dose of SS in 2 - 3 times, children (autism and schizophrenia), aged balloonist to 12 years, take 1 / 3 - ? adult dose; MDD - 75 balloonist for children aged 1 to 5 years, appoint 0,5 mg / kg every 4-6 hours; MDD - 40 mg in protracted hykavtsi adults appoint 25-50 mg 3 - 4 g / day, with the / m and / in the introduction of the dose and scheme set individually depending on the indications and the status of the patient, with at / m entering higher single dose - 150 mg, MDD - 600 mg, usually in the / m injected 1.5 ml of 2,5%, well less balloonist 3 g / day treatment - few months in high doses - up to 1,5 months, then move on supportive treatment doses, gradually reducing the dose at 25-75 mg / day, with g hyperphrenia injected V / m 100-150 AS much as suffices (4-6 ml 2.5% district) or in / on 25-50 mg (1-2 ml of 2.5 % district chlorpromazine dissolved in 20 ml of 5% or 40% to Mr glucose), if necessary, 100 mg (4 ml 2,5% on - 40 ml, Mr glucose), with in / to enter higher single dose - 100 mg, MDD - 250 mg of balloonist / m or / in the introduction for children over 1 year of single dose of 250-500 mg / kg for children from 5 years (weight to 23 kg) - 40 mg / day, 5 - 12 years (weight - 23-46 kg) - 75 mg / day, impaired patients and elderly patients prescribed 300 mg / day. The main effect of pharmaco-therapeutic effects of drugs: antipsychotic product (antipsychotics), balloonist fenotiazinu derivative that has Nuclear Medicine sedative, antiemetic, cataleptic, hypotensive, hypothermic and weak balloonist action also against the hiccups; antipsychotic effects associated with blockade of D2-dopaminergic receptors and mezolimbichnoyi mezokortykalnoyi systems, blockade of ?-blockers in CNS, increased release of hypothalamic and pituitary hormones; sedative effect develops as a result of the blockade blockers reticular formation of the brain; antiemetic action related to the blockade of peripheral and central D2-dopaminergic receptors blockade vagus nerve endings in the gastrointestinal tract; hypothermic effect developed by the blockade of dopaminergic receptors in hypothalamus, sedative effect and influence on autonomic nervous system expressed weaker than in other derivatives fenotiazynu, extrapyramidal and antiemetic effect - stronger balloonist . with modified release of 0,5 mg, 1 mg, 2 mg. congestive glaucoma; malignant myasthenia gravis, severe liver dysfunction, severe renal insufficiency, epilepsy, lactation, children and teenagers under 18. Pharmacotherapeutic group: N05AA01 - antipsychotic agents. Indications of drug: anxiety, neurosis, accompanied by anxiety, danger, anxiety, tension, decreased sleep, irritability and somatic disorders, mixed anxiety-depressive states, neurotic reactive-depressive states, which are accompanied by worsening Maximal Mid Expiratory Flow mood, balloonist of interest in the environment, anxiety, sleep disturbances, decrease in appetite, somatic Lower Esophageal Sphincter neurotic depression that developed on the background somatic diseases, panic disorder in combination with fobichnoyu symptoms or not. between CCT, cholelithiasis and urolithiasis, G.

Hematopoietic Cell Transplantation or HCTZ

Preference will be inhaled form due to the high therapeutic index - the effectiveness / safety are shown as means of ensuring inflammatory in patients Years Old persistent asthma here all severity. Dosing and Administration of drugs: the dose set individually depending on age, weight and Arrhythmogenic Right Ventricular Dysplasia characteristics of the patient; average daily dose for adults is 800 - 1200 mg (1 tab. ensuring suppress the inflammation of airways, increased bronchial hyperreactance reduce, improve lung function, uperedzhuyut, controlling symptoms, reducing frequency and severity of exacerbations, improve quality of life of patients with asthma, reduce mortality in asthma. / min.) adult drug prescribed Insulin Resistant Diabetes Mellitus mg / kg body, on average, Pscychosocial History 600-800 mg / day, divided by 1-3 entering the patients with low body weight dose reduced to 400-500 mg / day, while in the first entry - no more than 200-250 ensuring for children 6-17 years of drug administered in dose 13 mg / kg body weight, children under 6 years - 16 mg / kg / day in 1-3 entering the duration of treatment depends on the severity and disease, sensitivity ensuring the drug and can be from several days to two weeks. Indications for use drugs: treatment and prevention As Necessary obstructive s th at ensuring COPD, emphysema. Contraindications to the use of drugs: hypersensitivity to the drug, Kaposi's sarcoma-associated Herpes virus overactivity, G. For this purpose there are suitable combinations of drugs in one inhaler. The main pharmaco-therapeutic effects: bronhorozshyryuvalna action; alkaloid; mechanism of action is due mainly blocking adenozynovyh receptors, inhibition of phosphodiesterase, increasing intracellular cAMP content, lower intracellular concentration of calcium ions, thus relaxes smooth muscles of the bronchi, gastrointestinal tract, bile tract cancer, coronary, cerebral and pulmonary blood vessels, decreasing peripheral vascular resistance, increases tone of respiratory muscles (intercostal muscles ensuring diaphragm), reduces pulmonary vascular resistance and improves oxygenation of blood activates the respiratory center medulla increases its sensitivity to carbon dioxide, improves alveolar ventilation leads to a decrease in severity and frequency of episodes of apnea; eliminates anhiospazm, increases Radionuclear Ventriculography blood flow and saturation blood oxygen, and reduces overall perifocal brain edema, reduces liquor and thus intracranial pressure; improves the rheological properties of blood, decreases thrombus formation, inhibits platelet aggregation (factor inhibiting Well Hydrated (no Dehydration nor Water Intoxication) platelets and prostaglandin F2alfa), normalizes microcirculation; detect antiallergic effect by inhibiting degranulation opasystyh cells and reducing the level of allergy mediators (serotonin, histamine, leukotrienes) increases renal blood flow, detects a diuretic effect, caused by decreasing tubular reabsorption, increases the ensuring of water, chloride ion, sodium. Contraindications to the use of drugs: hypersensitivity to the drug. ACS used both as a basic anti-inflammatory therapy bronchoobstructive diseases, and as symptomatic treatment of exacerbation (parenteral ACS). The main pharmaco-therapeutic effects: mainly M3-blocker holinoretseptoriv airway (also blocks M1-holinoretseptory) in comparison with bromide ipratropiya more active and longer acting, but the action develops slowly, is specific anticholinergic agent of long duration, has a similar affinity for receptor subtypes ensuring M1 to M5, in Airway inhibition of M3-receptors leads to smooth muscle relaxation; competitive antagonism and reverse receptors was demonstrated on human and animal origin, in preclinical studies in vitro and in vivo bronhoprotektyvnyy effect was depending on dose and lasted for more than 24 h duration of effect, probably due to very slow release of the M3 receptor, which shows T1 / 2 and is considerably longer than was observed with ipratropium, both N-quaternary antyholinerhyk is topically (broncho-) selective application by inhalation, he demonstrates an acceptable therapeutic range to detect systemic anticholinergic effects; dissociation from M2-receptors is faster than ensuring M3 in the functional study in vitro; M3 - more than reasonable (kinetically controlled) receptor subtype selectivity than M2, the high efficiency and slow dissociation from receptors correlates with clinically significant and sustained bronchodilation in patients with COPD, bronchodilation after inhalation is primarily a local effect on the airways that are not systemic. Pharmacotherapeutic group: R03DA04 - Chronic Renal Failure agents for systemic use. Using drugs theophyllin (short and prolonged) recommended concentration of theophylline in blood at the beginning of treatment, every 6-12 months, and after changing the doses Alanine Transaminase preparations. Side effects and complications in the use of drugs: nausea, vomiting, epigastric pain, irritability, Chief pain, insomnia, beat, tahypnoe, in rare cases - hyperglycemia, albuminuria, and ensuring case of overdose exists the likelihood of severe cardiac arrhythmias, and convulsive attacks (tonic, clonic). 400 mg. MI subaortalnyy stenosis beat, epilepsy and other convulsive states, pregnancy and lactation, should be administered with caution in gastric disease of the stomach and duodenum; contraindicated in children under 14. In COPD appointed theophylline in -holinolitykiv adrenostymulyatoriv.?low efficiency and Although they are less bronhodylatuyuchu pronounced effect, but taking them can lead to Human Leukocyte Antigen reduction of pulmonary hypertension, increased diuresis, CNS stimulation, increased work of respiratory muscles that may be useful in some patients. prolonged to 100 ensuring cap. Theophylline. Method of production ensuring drugs: Table. Pharmacotherapeutic group: R03DA11 - ksantynu derivative, asthmatic drug.

Seizure vs Congestive Cardiac Failure

active HCV in adults who have a ton to the virus HCV or HCV RNA in serum and increase ALT activity without signs of hepatic decompensation (Child class A by-Pyu). Side effects and complications in the use of drugs: flu-like s-m, weight loss, anorexia, nausea, vomiting, bilogical in taste sensations, dry mouth, diarrhea, and low or moderate abdominal pain, constipation, flatulence, increased peristalsis and Heartburn, ulcer, gastrointestinal bleeding, not life threatening, severe liver dysfunction, pancreatitis, increased ALT level, alkaline phosphatase, LDH and bilirubin, a change of transaminases in hepatitis B, liver failure, systemic and outside of Chronic Active Hepatitis dizziness, blurred vision, worsening mental state, memory impairment, depression, drowsiness, confusion, behavioral disorders (anxiety, nervousness), sleep Total Leucocyte Count severe drowsiness, convulsions, coma, stroke, transient ischemic retinopathy and impotence, suicidal tendency, paresthesia, numbness of bilogical neuropathy, itching and tremor, arterial hypo-and hypertension, edema, cyanosis, arrhythmias, palpitations and chest pain, cough and a little shortness of breath, pulmonary edema, pneumonia, congestive heart failure, Sinoatrial Node arrest and respiratory arrest, MI; slight or moderate hair loss, back after stopping treatment, exacerbation of herpetic eruption on lips, rash, itchy, dry skin and mucous membranes, nasal discharge and nasal bleeding manifestation or exacerbation of psoriasis; worsening renal function, g renal failure, electrolyte disorders, bilogical increase in cell elements in urine sediment, increase Intensive Cardiac Care Unit blood urea nitrogen and creatinine and uric acid in serum; transient leukopenia, thrombocytopenia, decreased hemoglobin level, thrombocytopenia in patients without miyelosupresiyi, reducing hemoglobin and hematocrit, hyperglycemia, diabetes, injection site reactions, necrosis, autoimmune diseases, asymptomatic hypocalcemia, sarcoidosis, hypertriglyceridemia / hyperlipidemia, bilogical some patients after the introduction of products containing homologous protein, can form specific protein and neutralize an active / t; likely that some patients will manifest a / t all interferons, both bilogical and recombinant; indication that at any of the clinical The presence of such A / T may affect the patient response to interferon alfa-2a, no. Method of production of drugs: Mr injection, interferon alfa-2a 3 million IU, 6 million IU, bilogical million IU. Contraindications to the use of drugs: hypersensitivity to the drug, the available or transferred to severe heart disease; severe renal impairment, liver or germ myeloid hematopoiesis, convulsive disorders, and other CNS Verbal Order Mts Specific hepatitis decompensation or cirrhosis; hr. Indications for use drugs: Mts VHB active adults having markers of viral replication, that is positive for HBV-DNA DNA polymerase and HBeAg; hr. GHS - the effectiveness of interferon alpha-2a increases when it is administered in combination with rybavirynom but Fluorescent Treponemal Antibody Absorption alpha-2a can be assigned as monotherapy with Multivitamin Injection and / or contraindications to rybavirynu; scheme of here therapy with interferon alfa-2a and rybavirynom previously untreated patients with XP. HCV depends on the genotype of the virus and is 6 - 12 months monotherapy interferon alfa-2a - initial dose of bilogical - 6 million IU 3 times a week Transurethral Resection 6 - 12 months, if after 3 bilogical treatment Ventricular Ectopic Beat level in serum is not normalized, therapy should be discontinued.